Tagged with Strategy

Denmark Christof Bischoff, Country Director of AstraZeneca Denmark, draws on over two decades of international and national experience to navigate one of Europe’s most advanced yet complex healthcare environments. In this interview, he reflects on the affiliate’s evolution from a traditional commercial operation to a system-oriented partner driving innovation across clinical…

Denmark As Denmark sets its sights on becoming a global leader in life sciences by 2030, Morten Bødskov, Minister for Industry, Business, and Financial Affairs, outlines the strategic pillars of the country’s Life Science Strategy Toward 2030. With an unwavering commitment to strengthening Denmark’s competitive edge in the face of fierce…

Denmark Steve Wright, General Manager of Boehringer Ingelheim Denmark and Norway, shares insights on how the company is advancing its ambitious pipeline and aligning with Denmark’s national healthcare priorities. In this interview, Wright discusses Boehringer Ingelheim’s strategic focus on innovation, access, and prevention, while reflecting on the company’s evolving role in…

Switzerland Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in Zurich specialising in R&D, data management, and commercialisation. With 25 ongoing clinical trials per year, Switzerland is an important country…

Denmark Once a quiet legacy player in dermatology, LEO Pharma is re-emerging with renewed focus and ambition under CEO Christophe Bourdon. With global leadership experience at Amgen and Alexion, Bourdon is guiding the century-old company through a bold transformation, restoring profitability, embracing external innovation, and laying the groundwork for a potential…

Switzerland From humble beginnings in southern Switzerland to crossing the USD 1 billion revenue mark, IBSA has quietly redefined what it means to grow a pharmaceutical company, without fanfare, without mega-mergers, and without compromising its values. In this interview, Chief Commercial Officer & Chairman of the Executive Committee Luca Crippa unpacks…

Denmark Jakob Nielsen, CEO of Healthcare Denmark, discusses how Denmark has strengthened its role in global health diplomacy and life sciences since 2021. Nielsen highlights the country’s focus on strategic international partnerships, digitalisation, and patient-centric healthcare reform, positioning Denmark as a transparent and collaborative partner in addressing shared healthcare challenges. What…

China Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused biopharmaceutical companies. Launched with USD 5 million and no initial products, OcuMension now leads in China’s ophthalmology drug development, maintains rapid growth, and is preparing for global reach.…

Singapore Charles Stacey, President and CEO of Cerecin, discusses the company’s strategic direction and partnerships as it advances its Alzheimer’s treatment into Phase 3 trials. He highlights the importance of collaboration with global contract research organizations and large vendors during the clinical development phase. Stacey also shares insights into Cerecin’s approach…

Denmark Peter Halling, CEO of ALK, leads the century-old allergy immunotherapy innovator through a transformative phase focused on expanding patient access and innovation globally. In this interview, Halling discusses ALK’s Allergy+ growth strategy and response to rising allergy prevalence, unique “field to pharmacy” production model, and ambitions to balance strong European…

Denmark Home to a score of pioneering biopharma players, Denmark has recognized its life sciences industry as a cornerstone of the economy. After forming a public-private partnership forum in 2021, the Danish Life Sciences Council (DLSC), the government laid out an ambitious strategy for the sector. The DLSC has now taken…

Switzerland From its roots as a family-run ophthalmology business to its bold reinvention as a precision oncology biotech, CIS Biopharma is charting a distinctive course through the rapidly evolving life sciences landscape. Leading this transformation, CEO Christoph Schäfer shares the strategic rationale behind the company’s evolution, offering insight into how scientific…